Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
sargramostim · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| glioblastoma multiforme multipeptide vaccine IMA950 | BIOLOGICAL | - |
| sargramostim | BIOLOGICAL | - |
| temozolomide | DRUG | - |
| laboratory biomarker analysis | OTHER | - |
| pharmacological study | OTHER | - |
| adjuvant therapy | PROCEDURE | - |
| radiation therapy | RADIATION | - |
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed glioblastoma multiforme (astrocytoma WHO grade IV disease) * Newly diagnosed disease * Resectable tumor (not including patients undergoing biopsy only or tumors involving the brain stem or cerebellum) * Meets 1 of the followi...
Sargramostim is being studied for use in brain and central nervous system tumors, specifically in the treatment of newly diagnosed glioblastoma multiforme. It is administered as part of a vaccine therapy combined with temozolomide and radiation therapy. The drug is currently in clinical development for this indication.
Sargramostim is being developed by Immatics N.V., a biopharmaceutical company traded on the stock exchange under the ticker IMTX. The company is conducting clinical research on this drug for oncology applications, specifically targeting brain and central nervous system tumors.
Sargramostim is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 1 trial for sargramostim has been completed, and the drug remains under investigation for its safety and efficacy in treating brain and central nervous system tumors.
Sargramostim is associated with clinical trial NCT01222221, titled "Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme." This Phase 1 trial was completed and enrolled 45 participants in the United Kingdom. The trial was uncontrolled and did not use randomization or blinding.
Sargramostim is a monoclonal antibody, a type of drug designed to bind to specific proteins in the body. In the context of its clinical trial, it is used as part of a vaccine therapy for glioblastoma multiforme, a type of brain tumor. The specific molecular target of sargramostim is not disclosed in the available information.
Sargramostim is also known by other names, though specific alternative names are not provided in the available information. It is a distinct drug being developed by Immatics N.V. for oncology indications. Patients and healthcare providers should refer to the drug by its generic name, sargramostim, when discussing treatment options.